Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Frances Wang 2025 Apr 02, 16:00

USD/JPY Forecast: Analyzing Market Trends and Economic Indicators

Forex
Tommy Yap 2025 Apr 02, 16:00

Morning Note: U.S. Tariffs Shake Markets, Nikkei Sinks & Swiss Inflation Data Awaits

Morning Note USD
Frances Wang 2025 Apr 01, 16:00

Silver news today: Why has the silver price been volatile recently?

Commodities
three barrels of oil, neftechka, and American dollars against the background of a wooden table
Tommy Yap 2025 Mar 31, 21:00

Morning Note: US Jobs Data, Oil Steady on Tariffs, MicroStrategy BTC Bet

Oil Morning Note Cryptocurrencies
Frances Wang 2025 Mar 31, 16:00

Gold Prices Hit New Highs: What is Gold CFD trading?

Commodities
Frances Wang 2025 Mar 31, 16:00

Oil Markets Today: Oil Falls on OPEC+ Output Hike and Trump’s Tariffs

Commodities
Japan retail 
Tommy Yap 2025 Mar 29, 21:00

Morning Note: Japan Retail, China PMI, Germany Inflation

Japan Morning Note China
Tommy Yap 2025 Mar 29, 16:00

Week Ahead: U.S. Non-Farm Payrolls Coming Up: What to Expect

Forex Indices

정보

스프레드

0.06

스프레드(%)

1.0135 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 개장

목요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

수요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

847543744

발행 주식 수

137143008

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.83

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot